INS and obesity disorder: Disorders of glucose metabolism, particularly type 2 diabetes and obesity, remain major therapeutic challenges because they involve dysfunction across multiple tissues, including pancreatic β-cells, peripheral insulin-sensitive tissues, and immune cells.